Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Biologic therapy.

Duke University Medical Center, Durham, North Carolina, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Durham, North Carolina
Treatments:Biologic therapyHospital:Duke University Medical Center
Drugs:Journal:Link
Date:Jan 2004

Description:

Patients: This Phase II trial involved 57 patients with first recurrence of a glioblastoma who were previously treated with surgical resection, radiation, and usually chemotherapy underwent an open biopsy or resection at evaluation for confirmation of tumor recurrence.

Treatment: Treatment consisted of gefitinib. Gefitinib is a novel epidermal growth factor receptor tyrosine kinase inhibitor.

Toxicity: Grade 4 toxicities related to treatment included rash and diarrhea. (Grade 4 seizure and intracerebral hemorrhage were “deemed either unrelated or unlikely to be related to gefitinib use.”) Other toxicities included: conjunctivitis (grade 2-3), onycholysis (grade2-3), ALT elevation (grade 1-3), anorexia (grade1), weight loss (grade 1), and deep vein thrombosis (grade 3).

Results: Median overall survival was 9.2 months.

Correspondence: Jeremy N. Rich, MD




Back